CD8A and infection: Vaccine efficacy in the prophylactic vaccine trial, RV144, was greater in class I HLA A*02 positive participants than in HLA A*02 negative participants in a T-cell-based sieve analysis (20), and in a subset of participants in the HVTN505 trial, reduced infection risk was associated with high-level Env-specific CD8+ T cell responses (21).